RedFlag Index™ · #8 of 10 · NYSE: LLY

Eli Lilly and Company: enforcement record and regulatory exposure

Eli Lilly and Company scores 55 out of 100 on the RedFlag Index™ (October 2026), ranking #8 of ten tracked companies, with 6 documented cases of which 3 remain open.

Eli Lilly has paid about $3.0 billion in tracked penalties since 2000.

September 2026: Florida sued Eli Lilly, alleging it set Humalog's list price at about $280 a vial while returning about $210 to PBMs as rebates. The suit alleges uninsured patients pay the full list price. The case is unresolved.

The same complaint says Eli Lilly, Novo Nordisk, and Sanofi supply more than 90% of the world's insulin.

2009: Eli Lilly paid $1.415 billion over Zyprexa, including a $515 million criminal fine.

2005: Eli Lilly paid $36 million over Evista, including a $6 million criminal fine.

  1. State Enforcement

    Texas sues Sanofi over free nurse and support services kickback allegations

    Texas Attorney General Ken Paxton has sued Sanofi-Aventis U.S. LLC, alleging that its Free Nurse Program and Support Services Program amounted to in-kind kickbacks to providers under the Texas Health Care Program Fraud Prevention Act. The state seeks more than $1 million in monetary relief, including civil penalties, and an injunction.

  2. PBM Rebates

    Missouri sues 19 PBMs and insulin makers over alleged pricing scheme

    Missouri Attorney General Catherine Hanaway has sued 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to inflate insulin prices in violation of the Missouri Merchandising Practices Act. The state seeks injunctive relief, restitution, damages and disgorgement.

  3. Drug Pricing

    Oregon seeks $900 million from insulin makers and PBMs over pricing

    Oregon Attorney General Dan Rayfield has filed a $900 million lawsuit against Novo Nordisk, Sanofi, Eli Lilly, Express Scripts, CVS Caremark and Optum, alleging a coordinated scheme to inflate insulin and diabetes drug prices. The 173-page complaint was filed in Multnomah County Circuit Court.

  4. Drug Pricing

    Eli Lilly settles with Minnesota to cap insulin at $35 a month for uninsured residents

    Minnesota Attorney General Keith Ellison announced a settlement with Eli Lilly under which Lilly agreed to cap insulin prices at $35 per month for uninsured Minnesotans and donate insulin to free clinics serving low-income patients. No liability was admitted. The settlement built on Minnesota's 2020 Alec Smith Insulin Affordability Act.